Canopy Growth Announces Adjournment of 2026 Annual General and Special Meeting Due to Lack of Quorum

Canopy Growth Announces Adjournment of 2026 Annual General and Special Meeting Due to Lack of Quorum

  • Annual General and Special Meeting of Shareholders of Canopy Growth to reconvene on Friday, October 23, 2026, at 1:00 p.m. ET
  • Shareholders now have until Friday, October 23, 2026, at 9:00 a.m. ET to submit their votes

SMITHS FALLS, Ontario–(BUSINESS WIRE)–
Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced that, due to the requisite quorum not being present, its Annual General and Special Meeting of shareholders (the “Meeting”), scheduled for Friday, September 25, 2026, at 1:00 p.m. ET via live webcast, was convened and then adjourned.

The Meeting will reconvene on Friday, October 23, 2026, at 1:00 p.m. ET via live audio webcast at www.virtualshareholdermeeting.com/WEED2026, providing holders (“Shareholders”) of Canopy Growth common shares (the “Shares”) with additional time to vote.

During the adjournment period, the Company will continue to solicit votes with respect to the proposals set out in its definitive proxy statement dated August 7, 2026 (the “Proxy Statement”). Shareholders who have not yet voted are encouraged to do so as soon as possible.

Shareholders of record as of close of business on July 31, 2026, remain eligible to vote at the adjourned Meeting. Shareholders who have already voted do not need to vote again, and previously submitted proxies will remain valid.

Your Vote is Important

Under Nasdaq listing rules and the Company’s By-Laws, 33 1/3% of outstanding Shares entitled to vote must be present in person, by remote communication or by proxy at the Meeting for quorum to be achieved.

Shareholders who have not yet voted are encouraged to submit their vote before the new proxy voting deadline of 9:00 a.m. ET on October 23, 2026.

Most Shareholders who received a 16-digit control number from Broadridge Financial Solutions can vote:

Online: http://proxyvote.com

By Phone: 1-800-474-7493 (English) or 1-800-474-7501 (French)

By Mail: Using the prepaid envelope accompanying the Form of Proxy or Voting Instruction Form

Many Shareholders can also vote by contacting the Company’s proxy solicitation agent, Sodali & Co., at 1-833-830-8205 toll free in North America, 1-289-695-3075 collect outside North America, or by email at [email protected].

Shareholders who hold Shares at Interactive Brokers LLC can vote online at: http://proxypush.com using the provided control number.

Clients of Robinhood Securities, LLC who are eligible to vote will receive a voting notice by email from [email protected]. Voting is hosted by Say Technologies, with voting and materials available directly from the email.

The Proxy Statement and the Company’s 2026 fiscal annual report, which includes the Company’s 2026 fiscal year consolidated financial statements (collectively, the “Meeting Materials”) are filed on EDGAR at www.sec.gov and SEDAR+ under the Company’s profile at www.sedarplus.ca. The Meeting Materials are also available at: https://canopygrowth.com/agm/.

About Canopy Growth

Canopy Growth is a leading global company committed to bettering lives through cannabis. With a focus on cultivation excellence, quality, trust, innovation and disciplined execution, Canopy Growth is a consumer-centric company serving patients, consumers and partners alike.

The Company’s portfolio of owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, DeeLish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, as well as category-defining Storz & Bickel, delivers innovative cannabis products to consumers across Canada and beyond. It is also Canada’s leading provider of medical cannabis services through Spectrum Therapeutics, Abba Medix, Apollo, and Canada House Clinics.

The Company also holds an unconsolidated, non-controlling interest in Canopy USA, LLC, which provides exposure to the U.S. THC market.

Guided by its commitment to leadership, excellence, trust and innovation, Canopy Growth is working to shape a future where the plant is trusted for its ability to better lives.

For more information visit www.canopygrowth.com.

Media Contact: [email protected]

Investor Contact:[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Cannabis Retail Alternative Energy Specialty Energy Natural Resources

MEDIA:

Rubico Announces Record Date of Monday, September 28 and Ex-Dividend Date of Tuesday, October 6 for Previously-Announced 0.50 Common Shares Per Common Share Stock Dividend

ATHENS, Greece, Sept. 25, 2026 (GLOBE NEWSWIRE) — Rubico Inc. (Nasdaq: RUBI) (“Rubico,” or the “Company”), a global provider of shipping transportation services specializing in the ownership of vessels, announces that, in relation to the previously announced stock dividend of 0.50 common shares for each common share outstanding (the “Stock Dividend”), the Nasdaq Capital Market (“Nasdaq”) has determined that the ex-dividend date will be October 6, 2026. The Stock Dividend will be distributed on or about October 5, 2026 (the “Distribution Date”) to shareholders of record as of the close of business on September 28, 2026. No fractional shares will be issued in connection with the Stock Dividend; any fractional shares resulting from the Stock Dividend will be paid in cash based on the closing price of the Company’s common shares on Nasdaq on September 28, 2026.


As a result of “due bill” trading procedures expected to be established by Nasdaq, Rubico common shares are expected to trade with due bills from September 28, 2026 through and including the Distribution Date. Accordingly, holders of Rubico common shares as of September 28, 2026 will need to hold such shares through and including the Distribution Date in order to receive the Stock Dividend.


This would mean that holders who purchase Rubico common shares during the due bill period (even if the trades are to be settled after the due bill period) will be entitled to receive the Stock Dividend with respect to those shares. Conversely, sellers who sell Rubico common shares during the due bill period (even if the trades are to be settled after the due bill period) will not be entitled to the Stock Dividend with respect to those shares.


Due bills obligate a seller of securities to deliver the distribution payable on such securities to the buyer. The due bill obligations are customarily settled between the brokers representing buyers and sellers of the securities. The Company has no obligation for either the amount of the due bill or the processing of the due bill. Buyers and sellers of Rubico’s common shares should consult their brokers before trading to ensure they understand the effect of Nasdaq’s due bill procedures.

About the Company

Rubico Inc. is a global provider of shipping transportation services specializing in the ownership of vessels. The Company is an international owner and operator of two modern, fuel efficient, eco 157,000 dwt Suezmax tankers. Furthermore, the Company owns two 47,499 dwt MR tanker newbuildings scheduled for delivery in the third and fourth quarters of 2029 and a 60-meter newbuilding megayacht scheduled for delivery in the second quarter of 2027, which the Company intends to divest. In addition, the Company has entered into a share purchase agreement to acquire a shipowning company that owns one high-specification 47,499 dwt MR tanker newbuilding scheduled for delivery in the second quarter of 2029, with closing of this share purchase agreement to occur by September 30, 2026.

The Company is incorporated under the laws of the Republic of the Marshall Islands and has executive offices in Athens, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “RUBI”.

Please visit the Company’s website at: https://rubicoinc.com/

For further information please contact:

Nikolaos Papastratis
Chief Financial Officer
Rubico Inc.
Tel: +30 210 812 8107
Email: [email protected]

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts, including statements regarding the distribution of the Stock Dividend, the payment of cash in lieu of fractional shares and Nasdaq trading procedures.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections. Please see the Company’s filings with the Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.



UBS hires Financial Advisors John Pham and Jimmy Yip in Silicon Valley

UBS hires Financial Advisors John Pham and Jimmy Yip in Silicon Valley

Experienced team joins UBS offices in Palo Alto and San Jose, California

PALO ALTO, Calif. & SAN JOSE, Calif.–(BUSINESS WIRE)–
UBS today announced that Financial Advisors John Pham and Jimmy Yip have joined the firm’s offices in Palo Alto and San Jose, California. The team joins UBS from Merrill Lynch and will be part of the UBS San Francisco Market, led by Market Executive Emily de la Reguera and reports to Silicon Valley Market Director Jacqueline Kehoe.

“We are thrilled to welcome John, Jimmy, and their team to UBS,” said Emily de la Reguera. “John and Jimmy have built an exceptional team grounded in thoughtful advice, deep relationships and an unwavering commitment to their clients. Their experience serving the unique needs of Silicon Valley executives, entrepreneurs and families, together with the strength of our global wealth management platform, makes them an outstanding addition to UBS and an important part of our continued growth in the region.”

Market Director Jacqueline Kehoe worked closely with this team during her tenure at Merrill Lynch. The strong relationships and trust she developed with the team were instrumental in their decision to join UBS. “I have had the opportunity to work alongside this team and witness firsthand their dedication to delivering outstanding client service and fostering long-term relationships,“ said Jacqueline.

John Pham brings more than 22 years of experience advising Silicon Valley executives, entrepreneurs and families. He is known for his thoughtful approach to wealth management and his commitment to building lasting client relationships. His practice is centered on understanding each client’s complete financial picture and developing personalized strategies aligned with their long-term goals.

Jimmy Yip brings extensive financial services experience and a goals-based approach to advising working professionals, business owners and their families. He focuses on understanding each client’s goals, concerns and aspirations and developing tailored investment and wealth management strategies. Jimmy has worked in the financial services industry since 2004 and earned a bachelor’s degree in business marketing from San Jose State University.

John and Jimmy are joined by Client Associates Leslie Vinoya, Kimberly Russell and Randall Bane, who bring deep experience and a shared commitment to delivering exceptional client service.

Notes to Editors

About UBS

UBS is a leading and truly global wealth manager and the leading universal bank in Switzerland. It also provides diversified asset management solutions and focused investment banking capabilities. UBS manages 7.3 trillion dollars of invested assets as per the second quarter 2026. UBS helps clients achieve their financial goals through personalized advice, solutions and products. Headquartered in Zurich, Switzerland, the firm is operating in more than 50 markets around the globe. UBS Group shares are listed on the SIX Swiss Exchange and the New York Stock Exchange (NYSE).

https://www.ubs.com

© UBS 2026. All rights reserved. The key symbol and UBS are among the registered and unregistered trademarks of UBS.

Media Contact:

Christina Aquilina

[email protected]

Chloe White

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Logo
Logo

GOWell Technology Limited and Inflection Point Acquisition Corp. V Announce Closing of Business Combination

Combined company named “GOWell Energy Technology” and will trade on the NASDAQ under the ticker symbol “GOW”

SINGAPORE and NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) — GOWell Technology Limited (“GOWell” or the “Company”), a global one-stop-shop for innovative well logging solutions in the energy sector, today announced that it has completed its business combination with Inflection Point Acquisition Corp. V (NASDAQ: IPEX) (“Inflection Point”), a special purpose acquisition company (the “Business Combination”). The Business Combination was approved by Inflection Point shareholders in a special meeting held on September 3, 2026 and formally closed on September 25, 2026.

The new combined company will operate as “GOWell Energy Technology” (“GOWell Energy”). On September 28, 2026, GOWell Energy’s ordinary shares will begin trading on the NASDAQ under the ticker symbol “GOW”.

Concurrently with the closing of the Business Combination, GOWell completed the previously announced Closing PIPE investment, pursuant to which the investor purchased approximately $50 million of preferred shares and warrants of GOWell Energy. Together with the approximately $20 million private placement funded at the signing of the Business Combination Agreement in October 2025, the PIPE investments provided GOWell Energy with $70 million of gross proceeds, before deducting transaction fees and expenses, to support GOWell Energy’s growth initiatives and working capital.

Guillaume Borrel, GOWell’s CEO, commented: “The completion of our business combination caps 19 years of building GOWell into a wireline solutions developer and provider that service companies and operators can depend on downhole. Going public on NASDAQ gives us access to capital and the visibility to scale our sensing platform. GOWell’s technologies are mission critical to safely and efficiently securing energy sources, enabling us to deliver solutions faster to both traditional and energy transition markets in this time of increased energy volatility.”

Michael Blitzer, Chairman and CEO of Inflection Point, added: “For nearly two decades, GOWell has developed technologically advanced equipment, software and data analytics that have helped the world’s leading oilfield services companies address increasingly complex challenges. This has led to a resilient, cash-generative business with a track record of growth and margin expansion through industry cycles. As a public company, GOWell’s experienced executive team is poised to accelerate growth and consolidate its leading position in a fragmented industry.”

Advisors

Haitong International Securities (USA) Inc. acted as financial and capital markets advisor to GOWell. Cantor Fitzgerald & Co. and Cohen & Company Capital Markets, a division of Cohen & Company Securities, LLC, served as lead financial and capital markets advisors to Inflection Point. White & Case LLP served as legal counsel to Inflection Point, and Hunter Taubman Fischer & Li LLC served as legal counsel to GOWell. Conyers Dill & Pearman served as Cayman Islands counsel to Inflection Point and Ogier (Cayman) LLP served as Cayman Islands counsel to GOWell. Gateway Group served as investor relations and public relations advisor for the transaction.

About GOWell Technology Limited

GOWell Technology Limited is an international company that provides a wide range of innovative well logging technologies and distributed sensing solutions for energy companies globally. The Company maintains a multi-disciplinary research and development team with a robust patent portfolio of technology aimed to solve complex industry challenges. GOWell’s solutions can be applied to a wide range of wells from traditional energy to energy transition. The Company has a global, diverse customer base with long-term relationships with the key major oil service companies and operators in the energy sector. Headquartered in Singapore, GOWell has a global manufacturing and procurement network, with regional hubs in the United States and UAE in addition to regional operations in more than 50 countries.

For more information about GOWell Technology Limited, visit www.gowell.energy.

About Inflection Point Acquisition Corp. V

Inflection Point Acquisition Corp. V (NASDAQ: IPEX) was a blank check company incorporated on May 31, 2024 in the Cayman Islands as an exempted company, for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

Forward Looking Statements

This press release includes or may include “forward-looking statements” regarding, among other things, the plans, strategies and prospects, both business and financial, of Inflection Point, GOWell Energy and GOWell. These statements are based on the beliefs and assumptions of the management of Inflection Point, GOWell Energy and GOWell. Although the parties believe that their respective plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, none of Inflection Point, GOWell Energy or GOWell can assure you that they will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, and any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “predicts,” “projects,” “forecasts,” “may,” “might,” “will,” “could,” “should,” “would,” “seeks,” “plans,” “scheduled,” “possible,” “continue,” “potential,” “anticipates” or “intends” or similar expressions; provided that the absence of these does not means that a statement is not forward-looking. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release might not occur, and our actual results could differ materially from those anticipated in these forward-looking statements.

Important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include: general economic, political and business conditions; the outcome of any legal proceedings that may be instituted against the parties; the anticipated capitalization and enterprise value of GOWell Energy following the consummation of the Business Combination; the ability of GOWell Energy to issue equity, equity-linked or other securities in the future; failure to realize the anticipated benefits of the Business Combination; the risks related to the rollout of GOWell’s business and the timing of expected business milestones; the ability of GOWell Energy to execute its growth strategy, manage growth profitably and retain its key employees; the ability of GOWell Energy to obtain or maintain the listing of its securities on the NASDAQ Stock Market LLC following the Business Combination; and other risks and uncertainties indicated in the Proxy Statement/Prospectus and in GOWell Energy’s subsequent filings with the Securities and Exchange Commission. Undue reliance should not be placed upon the forward-looking statements.

These forward-looking statements are made only as of the date of this press release. Neither Inflection Point, GOWell Energy, nor any of their respective affiliates undertake any obligation to publicly update or revise any forward-looking statement contained in this press release, whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations Contact:

Gateway Group
Georg Venturatos, Patrick Hall
949-574-3860
[email protected]

Media Relations Contact:

Gateway Group
Zach Kadletz, Ryan Deloney
949-574-3860
[email protected]



HII Hosts National Commission on the Future of The Navy at Ingalls Shipbuilding

PASCAGOULA, Miss., Sept. 25, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) welcomed members of the National Commission on the Future of the Navy (FNC) to its Ingalls Shipbuilding division Thursday as part of the commission’s nationwide review to develop recommendations for strengthening American seapower.

The visit provided commission members with a firsthand look at the shipbuilding capabilities, workforce training and industrial investments that support the Navy’s future fleet requirements. As part of its comprehensive study of naval strategy, resources, force structure and the industrial base, the commission is assessing the nation’s shipbuilding capacity and long-term production needs.

“A strong Navy relies on a capable and resilient industrial base,” Commissioner Mitch Waldman said. “We are grateful for the opportunity to see firsthand the significant industrial capacity and workforce capability that Ingalls Shipbuilding provides as the commission continues to assess the nation’s ability to design, build and sustain the future Navy.”

During the visit, commission members toured key production and training areas, including the Flight III Arleigh Burke-class destroyer Jeremiah Denton (DDG 129), the Virtual Reality Welding Lab and the Maritime Training Academy. The tour highlighted the pace and scale of Ingalls’ operations, as well as major infrastructure investments designed to support increased throughput across the U.S. maritime industrial base.

A photo accompanying this release is available at: http://hii.com/news/hii-hosts-national-commission-on-the-future-of-the-navy-at-ingalls-shipbuilding/.

“Ingalls shipbuilders bring unmatched skill and dedication to every ship we build, and it was a privilege to show the commission how their work in the shipyard directly supports the fleet,” said Eric Crooker, Ingalls vice president of program management. “With more than 87 years of experience building ships for the U.S. Navy, and over a dozen ships in active construction, our team’s dedication and upcoming ship deliveries demonstrate the strength of our workforce and the capability we provide to the nation.”

With 13 ships in construction and three deliveries planned in the next year, Ingalls Shipbuilding offers a firsthand view of the production capacity and workforce capabilities central to meeting future fleet requirements. The shipyard’s recent progress through its distributed shipbuilding program further illustrates its role in the broader maritime industrial base.

Congress established the FNC to provide an independent review of naval force structure, shipbuilding performance and industrial-base requirements. Public hearings began in March 2026, with initial findings expected in January 2027.

As America’s largest shipbuilder, HII supports national defense by building and maintaining the Navy and Marine Corps ships that underpin U.S. seapower. Through investments in advanced digital and automated production technologies, workforce development and industrial-base capacity, HII works to support the readiness and sustainment of the nation’s fleet.

For more information about HII’s Ingalls Shipbuilding division, visit hii.com/ingalls-shipbuilding.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 45,000 strong. For more information, visit:

Contact:
Kimberly K. Aguillard
[email protected]
228-355-5663

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a96e7c21-b940-4853-a8f2-67affed0db53



Powering Community Resilience, Bloom Energy Supports First Responders in State College during ESPN College Campus Tour

Powering Community Resilience, Bloom Energy Supports First Responders in State College during ESPN College Campus Tour

Ahead of the Nittany Lions-Badgers face-off, Bloom recognized firefighters and first responders as part of its focus on community resilience

SAN JOSE, Calif.–(BUSINESS WIRE)–
Bloom Energy (NYSE: BE) continued its season-long partnership with ESPN Radio’s College Campus Tour powered by Bloom this week in State College, Pennsylvania.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925045354/en/

Before the Penn State-Wisconsin game, Bloom Energy visited the Alpha Fire Company to present a $10,000 donation to support the firefighters, first responders, and public servants who have been protecting the State College community since 1899.

Alpha Fire Company is an all-volunteer department that responds to a wide range of emergencies beyond fires, including fire prevention and traffic safety at emergencies. Protecting approximately 130,000 people across State College Borough, College Township, Ferguson Township, Patton Township, and the Penn State University campus, it is the third-largest fire department in Pennsylvania by population served.

“For more than a century, Alpha Fire Company has been a trusted presence in the State College community, serving neighbors during emergencies and helping keep people safe every day,” said Natalie Sunderland, Chief Marketing Officer at Bloom Energy. “Their volunteers represent the very best of community service, and we are proud to support the firefighters and first responders whose dedication protects communities across the State College region. We also thank State Representatives Scott Conklin and Paul Takac for joining us and for their continued support of the people and organizations that strengthen community resilience.”

“What makes Alpha Fire Company special is that service here creates opportunities that can change lives,” said Brian Bittner, Fire Chief of Alpha Fire Company. “We have more than 100 volunteers, and close to one third are Penn State students who live and serve at the firehouse while pursuing their education. Many have been able to graduate while saving money and launching their careers, all while giving back to the community. Support from organizations like Bloom Energy helps us continue investing in our people, our equipment, and our mission to serve.”

Bloom will also be onsite Saturday during the pregame tailgate where fans can take part in an interactive game and learn more about the company’s work powering essential services in communities nationwide.

Upcoming Confirmed 2026 Tour Stops

  • October 10 – Gainesville, Florida | South Carolina at Florida

  • October 17 – Austin, Texas | Florida at Texas

  • November 7 – Oxford, Mississippi | Georgia at Ole Miss

  • November 14 – Baton Rouge, Louisiana | Texas at LSU

  • November 21 – Lincoln, Nebraska | Ohio State at Nebraska

About Bloom Energy

Bloom Energy empowers enterprises to meet soaring energy demands and responsibly take charge of their power needs. The company’s fuel cell systems provide ultra-reliable, clean and highly scalable onsite electricity for Fortune 500 customers around the world, including data centers, semiconductor manufacturing, large utilities and other commercial and industrial sectors, as well as mission-critical organizations in local communities, such as hospitals, college campuses and retailers. Headquartered in Silicon Valley, Bloom Energy employs more than 2,000 people worldwide and manufactures its systems in the United States. For more information, visit BloomEnergy.com.

Forward-Looking Statements

This press release contains certain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will” and “would” or the negative of these words or similar terms or expressions that concern Bloom’s expectations, strategy, priorities, plans or intentions. These forward-looking statements include, but are not limited to, the impact of the contribution to the Alpha Fire Company. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, but not limited to, risks and uncertainties detailed in Bloom’s SEC filings. More information on potential risks and uncertainties that may impact Bloom’s business are set forth in Bloom’s periodic reports filed with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 9, 2026, its Quarterly Reports on Form 10-Q for the quarter ended March 31, 2026 and June 30, 2026, filed with the SEC on April 29, 2026 and July 28, 2026, respectively, as well as subsequent reports filed with or furnished to the SEC. Bloom assumes no obligation to, and does not intend to, update any such forward-looking statements.

Media Contact

Katja Gagen

[email protected]

KEYWORDS: United States North America California Pennsylvania

INDUSTRY KEYWORDS: Football Entertainment Other Energy Public Safety Law Enforcement/Emergency Services Public Policy/Government Alternative Energy Energy Other Philanthropy Philanthropy Sports University Education TV and Radio

MEDIA:

Photo
Photo
Logo
Logo

Chase Launches Data Security Center to Help Customers Manage Connected Apps and Third-Party Data Sharing

Chase Launches Data Security Center to Help Customers Manage Connected Apps and Third-Party Data Sharing

A new experience designed to give customers clearer information and simpler controls for understanding and managing connected-app access

NEW YORK–(BUSINESS WIRE)–
Today, Chase announced it has begun a phased rollout of its new Data Security Center, giving customers a clearer, simpler way to understand and manage how their financial data is shared with third-party apps. The experience is designed to make data sharing more visible and actionable, helping customers better understand where their data is being shared, make informed decisions about connected apps and maintain control over those connections over time.

The Data Security Center gives customers a central location to see which apps are connected to their Chase accounts, better understand what information is being shared and take action when they want to change or stop sharing. Customers can access the Data Security Center directly through the Chase Mobile® app, where they can review connected apps, manage permissions, adjust access duration, manage linked accounts, or unlink an app.

“Customers should be in control of their financial data, and that starts with giving them a clear view of where it’s going and straightforward tools to manage it,” said Melissa Feldsher, Head of Payments, Trust & Security and Open Banking at Chase. “The Data Security Center empowers customers to understand what’s connected, see what information is being shared and make informed decisions about those connections over time.”

The new experience is an evolution of how Chase helps customers manage third-party data sharing. While some account-linking features were already available in the Chase Mobile App, the new Data Security Center brings those capabilities together in a centralized destination with clearer information, education and management tools – giving customers a more complete view of their connected apps and data sharing.

Through the Data Security Center, customers can:

  • View apps connected to their Chase accounts

  • Review information about data sharing and connected-app activity

  • Manage app permissions

  • Adjust how long an app can access their data

  • Select which eligible accounts are linked to an app

  • Unlink connections where applicable

  • Access plain-language education and FAQs about third-party data sharing

Customers should only share data with apps they trust, review permissions regularly and use the Data Security Center to manage access.

About Chase

Chase is the U.S. consumer and commercial banking business of JPMorgan Chase & Co. (NYSE: JPM), a leading financial services firm based in the United States of America with operations worldwide, assets of $5 trillion and $375 billion in stockholders’ equity as of June 30, 2026. Chase serves more than 87 million consumers and 7.5 million small businesses with a broad range of financial services, including personal banking, credit cards, mortgages, auto financing, investment advice, small business loans and payment processing. Customers can choose how and where they want to bank: 5,100 branches in 48 states and the District of Columbia, 14,500 ATMs, mobile, online and by phone. For more information, go to chase.com.

Media Contact

Emma Eatman

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Other Professional Services Finance Banking Professional Services Technology Fintech Other Technology Security

MEDIA:

Logo
Logo

Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its direct cytotoxic activity

HOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced new preclinical data indicating that the antitumor activity of its lead drug candidate, Annamycin (naxtarubicin), in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity. The findings are being presented at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, held September 25–28, 2026 in San Diego, California.

In preclinical models of pancreatic cancer, Annamycin’s antitumor activity appears to depend in part on CD8+ T cells, the immune system’s primary tumor-killing cells. The finding suggests Annamycin may do more than kill cancer cells directly; it may also expose tumors that are typically considered immunologically “cold” to immune attack.

Pancreatic cancer is among the most treatment-resistant solid tumors, and its characteristically “cold” immune microenvironment is one reason checkpoint inhibitors have shown limited single-agent activity in the disease. Preclinical evidence that Annamycin’s activity is partly immune-mediated points to a potential basis for combination approaches, and complements the immune-modulating mechanism of the Company’s WP1066 program.

Title:
“Turning cold pancreatic tumors hot: Antitumor activity of Annamycin is partially mediated by CD8+ T cell cytotoxicity”

Author/Presenter: Angela T. Alistar, MD, Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center
Congress: AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development
Dates: September 25–28, 2026
Location: Hilton San Diego Bayfront, San Diego, California

These findings were generated in preclinical models. Preclinical results may not be predictive of results in humans, and Annamycin is not currently in clinical development for the treatment of pancreatic cancer.

The abstract for this presentation was published today as a supplement to the September 15, 2026 issue of Cancer Research.

“Annamycin represents a fundamental re-engineering of the anthracycline, one designed to increase efficacy and avoid multidrug resistance and the cardiotoxicity of currently prescribed agents,” said Walter Klemp, Chairman, President and Chief Executive Officer of Moleculin. “These data point to an unexpected additional benefit. In preclinical models of pancreatic cancer, Annamycin’s antitumor activity appears to depend in part on the immune system. If that observation holds, it broadens both where Annamycin might be useful and how it might be combined.”

Annamycin’s lead clinical program remains the ongoing MIRACLE trial evaluating AnnAraC in patients with relapsed or refractory acute myeloid leukemia (AML), which is the Company’s primary development focus and the basis of its near-term milestones. The pancreatic cancer findings described above are preclinical and are not part of the MIRACLE trial.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 2/3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML, the potential immune-mediated mechanism of action of Annamycin, the relevance of preclinical findings in pancreatic cancer to the treatment of human disease, and the potential for Annamycin to be combined with other agents. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]



Honeywell Technologies Announces Quarterly Dividend

Honeywell Technologies Announces Quarterly Dividend

CHARLOTTE, N.C.–(BUSINESS WIRE)–
Honeywell Technologies (NASDAQ: HON) today announced that its Board of Directors has declared a quarterly dividend payment of $0.70 per share on the Company’s common stock. The dividend is payable on December 4, 2026, out of surplus to holders of record at the close of business on November 13, 2026.

About Honeywell Technologies

Honeywell Technologies is a global, pure-play automation company with a legacy of innovating to help solve the world’s most mission-critical challenges, enhancing the quality of life for people and communities around the world. We serve the building, industrial, and process sectors with a broad portfolio of services, solutions, and products, underpinned by our Honeywell Technologies Accelerator operating system and Honeywell Technologies Forge intelligence layer. By combining the deep domain expertise of our more than 50,000 employees with decades of data from our global installed base, we are uniquely positioned to lead the industrial sector’s transition from automation to autonomy. For more news and information on Honeywell Technologies, please visit Honeywell Technologies Newsroom.

Forward-Looking Statements

We describe many of the trends and other factors that drive our business and future results in this release. Such discussions contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). Forward-looking statements are those that address activities, events, or developments that we or our management intend, expect, project, believe, or anticipate will or may occur in the future. They are based on management’s assumptions and assessments in light of past experience and trends, current economic and industry conditions, expected future developments, and other relevant factors, many of which are difficult to predict and outside of our control. They are not guarantees of future performance, and actual results, developments, and business decisions may differ significantly from those envisaged by our forward-looking statements. We do not undertake to update or revise any of our forward-looking statements, except as required by applicable securities law. Our forward-looking statements are also subject to material risks and uncertainties, including ongoing macroeconomic and geopolitical risks, such as changes in or application of trade and tax laws and policies, including the impacts of tariffs and other trade barriers and restrictions, lower GDP growth or recession in the U.S. or globally, supply chain disruptions, capital markets volatility, inflation, and certain regional conflicts, including ongoing conflicts in the Middle East, that can affect our performance in both the near- and long-term. In addition, no assurance can be given that any plan, initiative, projection, goal, commitment, expectation, or prospect set forth in this release can or will be achieved. These forward-looking statements should be considered in light of the information included in this release, our Form 10-K, and our other filings with the Securities and Exchange Commission. Any forward-looking plans described herein are not final and may be modified or abandoned at any time.

HON-D

Source: Honeywell Technologies

Media

Stacey Jones

(980) 378-6258

[email protected]

Investor Relations

Mark Macaluso

(704) 627-6118

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Electronic Design Automation Data Management Technology Manufacturing Software Other Manufacturing Hardware

MEDIA:

Logo
Logo

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

  • SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model – 

  • Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy –

  • SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009 activity against MYC-driven pancreatic cancer biology –

NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced preclinical data from studies evaluating SLS009 (tambiciclib), its highly selective cyclin-dependent kinases 9 (CDK9) inhibitor, in patient-derived organoid models of pancreatic ductal adenocarcinoma (PDAC). The data are being presented at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, being held September 25–28, 2026, in San Diego. The timing of this announcement reflects AACR’s embargo policy, under which the data presented at the conference were restricted from publication until 1:00 p.m. ET today.

The studies, conducted in collaboration with researchers at the University of Wisconsin–Madison, evaluated SLS009 in MYC-amplified PDAC models, including a model resistant to the recently approved RAS inhibitor daraxonrasib (RMC-6236), as well as in combination with the BET inhibitor ZEN3694. MYC amplification is a biologically recognized mechanism of RAS targeting resistance.

“These findings provide encouraging preclinical evidence that CDK9 inhibition may enhance the activity of RAS-directed therapy in pancreatic cancer, including in the setting of MYC-associated resistance,” said Dragan Cicic, MD, Senior Vice President, Clinical Development of SELLAS. “In a daraxonrasib-resistant patient-derived model, SLS009 demonstrated substantially greater activity than daraxonrasib alone and further increased apoptosis and necrosis when the two agents were combined. Together with the synergistic activity observed with BET inhibition, these data support a broader strategy of using SLS009 to disrupt transcriptional programs that may contribute to resistance to RAS-targeted therapies and provide a strong rationale for further evaluation in pancreatic cancer patients.”

In a MYC-amplified, daraxonrasib-resistant patient-derived PDAC organoid model, SLS009 at 200 nM, daraxonrasib at 100 nM, and the combination of both agents were evaluated. Daraxonrasib was administered continuously, while SLS009 was removed after 24 hours to approximate its in vivo pharmacokinetic profile, with apoptosis and necrosis assessed at 72 hours.

A separate MYC-amplified patient-derived PDAC organoid model evaluated SLS009 in combination with the BET inhibitor ZEN3694. The combination demonstrated synergistic activity, including increased cancer cell death and sustained suppression of MYC transcription. Notably, these effects were observed at a ZEN3694 concentration substantially below reported physiologically achievable exposure levels.

Key findings:

  • SLS009 demonstrated substantially greater single-agent activity than daraxonrasib in the daraxonrasib-resistant model, inducing 17.9% apoptosis versus 2.8% with daraxonrasib and 14.5% necrosis versus 2.7%.
  • The combination of SLS009 and daraxonrasib further increased cancer cell death, inducing 36.5% apoptosis and 30.6% necrosis, compared with 17.9% and 14.5%, respectively, with SLS009 alone and 2.8% and 2.7%, respectively, with daraxonrasib monotherapy.
  • SLS009 combined with ZEN3694 demonstrated synergistic activity, producing greater apoptosis and necrosis than either agent alone.
  • The SLS009/ZEN3694 combination produced sustained suppression of MYC RNA and reduced expression of MYC and MCL-1 proteins, consistent with disruption of transcriptional pathways supporting tumor cell survival.

Together, the findings support further investigation of CDK9 inhibition as a strategy to enhance RAS-directed therapy and potentially address MYC-associated resistance in pancreatic cancer. The BET combination data provide additional mechanistic support for SLS009-based approaches designed to disrupt MYC-dependent transcriptional programs and suggest the potential to enhance BET inhibition at lower drug exposures.

“MYC is a particularly challenging oncogenic driver because it has historically been difficult to target directly,” said Jeremy D. Kratz, MD, Assistant Professor of Medicine and Principal Investigator at the University of Wisconsin–Madison. “Across these studies, CDK9 inhibition produced substantial activity in MYC-amplified pancreatic cancer models through two distinct therapeutic strategies. The activity of SLS009 supports its activity in a model with de novo daraxonrasib-resistance and together with the synergistic transcriptional suppression observed with BET inhibition, provides a strong rationale for further investigation of SLS009-based combinations in molecularly defined subsets of pancreatic cancer.”

Poster presentation details:

Title: Elucidating MYC allelic imbalance and therapeutic response in pancreatic ductal adenocarcinoma via patient-derived organoids
Authors: Sawyer AG, Flannagan LE, Esguerra PN, Hossan MS, Kratz JD
Poster Number: A036 – September 27, 2026: 5-7pm PST

Title: Synthetic Lethality Through Combined BET and CDK9 Inhibition in MYC-Amplified Pancreatic Ductal Adenocarcinoma
Authors: Esguerra PN, Cadarso M, Livingwell S, Hossan MD, Wong O, Kratz JD
Poster Number: B127 – September 27, 2026: 5-7pm PST

Title: Targeting dual CDK9 and KRASG12D selective inhibition as a novel combination therapy in pancreatic ductal adenocarcinoma
Authors: Cadarso M, Esguerra P, Flannagan L, Hossan MS, Kratz JD
Poster Number: B043 – September 27, 2026: 5-7pm PST

The posters will be available on SELLAS’ website following the conference.

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) – potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 19, 2026 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact

John Fraunces
Managing Director
LifeSci Advisors, LLC
[email protected]

Media Contact

Joan Bosisio
VP, Scientific & Medical Communications
Simpson Healthcare
[email protected]